# Wellcome Leap Psilocybin for OUD

> **NCT06786325** · PHASE2 · RECRUITING · sponsor: **Anna Rose Childress, Ph.D.** · enrollment: 36 (estimated)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT06786325
- **Lead sponsor:** Anna Rose Childress, Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2027-06
- **Final completion:** 2027-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06786325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06786325, "Wellcome Leap Psilocybin for OUD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06786325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*